Freshservice. The official website for Beam Therapeutics is www.beamtx.com. MarketBeat's community ratings are surveys of what our community members think about Beam Therapeutics and other stocks. beam $97.06 $2.98 3.2% Price as of January 12, 2021, 9:00 p.m. EST View Interactive BEAM Charts Nachrichten zur Aktie Suntory Beverage & Food Limited | A1WZT4 | STBFF | JP3336560002 Suntory Beverage & Food Limited ADR (STBFY) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Vote “Underperform” if you believe BEAM will underperform the S&P 500 over the long term. Beam Therapeutics' stock was trading at $21.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Beam Therapeutics does not have a long track record of dividend growth. PRESS RELEASES. Vote “Outperform” if you believe BEAM will outperform the S&P 500 over the long term. News & Research. Beam (NYSE: BEAM) stock jumped 26% on news that it would be acquired by Japan’s Suntory. Lodgify. Suntory Beverage & Food Limited is a Japanese multinational brewing and distilling company group. Beam Therapeutics Announces Pricing Of Public Offering Of Common Stock. Baidu Analytics. Earnings for Beam Therapeutics are expected to grow in the coming year, from ($3.02) to ($2.82) per share. Beam Therapeutics employs 166 workers across the globe. Stocks sink, S&P 500 drops 1% as concerns over new virus strain in UK, restrictions weigh Suntory's Tech Stack. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Beam Suntory Now Focuses On Long Chicago. Beam Therapeutics started at outperform with $32 stock price target at Wedbush Mar. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. According to analysts' consensus price target of $33.60, Beam Therapeutics has a forecasted downside of 69.8% from its current price of $111.32. STBFY | A complete STBFY overview by MarketWatch. September 27, 2019 - by Arfan - Leave a Comment. Beam Suntory carefully crafts your favorites and new classics ready to be explored. Trading Ideas. MicroAd. Get short term trading ideas from the MarketBeat Idea Engine. BEAM: NYSE (Stock) Beam Inc. Dividend policy None Price as of: NOV 23, 11:00 AM EDT $42.47 +0.84 +2.02% BEAM: NYSE (Stock) Beam Inc. Dividend policy None Price as of: NOV 23, 11:00 AM EDT $42.47 +0.84 +2.02% Watchlist Overview. See More Acquisitions & Subsidiaries. On average, they anticipate Beam Therapeutics' share price to reach $33.60 in the next year. View which stocks have been most impacted by COVID-19. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. Expert: “There is Still Time to Profit from the Cannabis Boom”. © American Consumer News, LLC dba MarketBeat® 2010-2021. MarketBeat just released five new trading ideas, but Beam Therapeutics wasn't one of them. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Sep 30, 2020 8:46 PM EDT. Lodgify . Beam Suntory brands have been bringing people together for more than 200 years. In the past three months, Beam Therapeutics insiders have not sold or bought any company stock. KushCo: A Cannabis Stock That Could be Fire, Defi Is The Next Generation For Cryptocurrency Investors, Village Farms International (NASDAQ: VFF) Stock is a Unique Cannabis ESG Play, JP Morgan Chase (NYSE:JPM) Is A Buy On Post-Earnings Weakness, Buy Pure Storage (NASDAQ: PSTG) Stock on Pullback Levels Here, Exxon’s (NYSE:XOM) 7% Yield Is A Buy And Hold For 2021, Here’s Where to Buy Dropbox (NASDAQ: DBX) Shares on Pullbacks, 3 Stocks that Could Ride the Blue Wave to Big Gains, 7 Cryptocurrencies That Are Leading The Market Higher, 7 Stocks to Support Your New Year’s Resolutions, 7 Things You Need To Know About Cryptocurrency, 7 Stocks to Buy As Americans Receive Stimulus Checks, 7 Outdoor Recreation Stocks For Growth And Dividends, 8 EV Stocks To Electrify Your Growth Portfolio, 7 Cloud Computing Stocks to Lift Your Portfolio to New Heights, 7 Infrastructure Stocks That May Help Rebuild America, view Wall Street analyst' top-rated stocks, Receive Analysts' Upgrades and Downgrades Daily. Beam Suntory ist ein Spirituosenhersteller mit Sitz in Deerfield, Illinois, USA.Das Unternehmen gehört dem japanischen Getränkehersteller Suntory.Beam Suntory entstand, als Suntory im April 2014 das Spirituosenunternehmen Beam Inc. für 13,6 Milliarden US-Dollar kaufte. See more technologies. Beam Therapeutics Inc. (NASDAQ:BEAM) issued its quarterly earnings results on Tuesday, November, 10th. Freshworks. The stock ticker symbol is SAB.L. BEAM SUNTORY INC (NYSE:) : Stock quote, stock chart, quotes, analysis, advice, financials and news for share BEAM SUNTORY INC | Nyse: | Nyse Beam Suntory. Suntory Beverage & Food Ltd trades on the Tokyo Stock Exchange (2587). 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 6 brokers have issued 1 year target prices for Beam Therapeutics' stock. Our world-renowned bourbons, Japanese whiskies, single malt scotches, tequilas and cognac are perfect for any occasion, whether it's a celebration in Kentucky, after-work drink in Tokyo, or a reunion in Madrid. Looking back at BEAM historical stock prices for the last five trading days, on November 23, 2020, BEAM opened at $42.15, traded as high as $42.90 and as low as $41.38, and closed at $42.47. Beam Therapeutics Inc., a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. On January 13, 2014, Suntory (headquartered in Osaka, Japan) announced a deal to buy Beam Inc. for about $13.6 billion. Company Profile. In connection with the Merger, the New York Stock Exchange (“ NYSE ”) filed a Form 25 (the “ Common Stock Form 25 ”) on the Closing Date to delist shares of Beam’s common stock, par value $3.125 per share (the “ Common Stock Payout History. Currency in USD. The company can be reached via phone at 857-327-8775 or via email at [email protected]. FreakOut. Learn about STBFY (PINX) with our data and independent analysis including price, star rating, valuation, dividends, and financials. Tokyo. He’s now moved $3.8 BILLION in a tiny niche of the tech sector billionaires are flocking to…, Start Your Risk-Free Trial Subscription Here. Beam Therapeutics (BEAM) has the following price history information. Beam Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 29th 2021. By GlobeNewswire. The P/E ratio of Beam Therapeutics is -7.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. By. STBFY Stock Price | Suntory Beverage & Food Ltd. ADR Stock Quote (U.S.: OTC) | MarketWatch. Identify stocks that meet your criteria using seven unique stock screeners. By. View breaking news headlines for BEAM stock from trusted media outlets at MarketBeat. Pernod looks for more bolt-on deals after U.S. buy, Activist investors see Ackman-Valeant deal as a model to follow, EU approves $13.6 billion Suntory, Beam deal, Ackman, Valeant team up to bid for Allergan in unusual pairing, Diageo bids $1.9 billion to take majority in India's United Spirits, EU to clear $13.6 billion Suntory, Beam deal without conditions - source, Dean Foods says exploring Morningstar sale. Established in 1899, it is one of the oldest companies in the distribution of alcoholic beverages in Japan, and makes Japanese whisky. The company issued 6,300,000 shares at $15.00-$17.00 per share. Beam Suntory is mixing a cocktail of culture as it moves forward as one company, drawing inspiration from Beam's 219-year U.S. heritage and Suntory's 115 … View our earnings forecast for Beam Therapeutics. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. View our full suite of financial calendars and market data tables, all for free. The acquisition was completed in April 2014, for a final cost of about $16 billion, when it was announced that Beam would become a subsidiary named "Beam Suntory." High institutional ownership can be a signal of strong market trust in this company. Beam Therapeutics has received 9 “outperform” votes. Beam Therapeutics had a negative net margin of 529,075.00% and a negative return on equity of 103.41%. Payout Estimate. The company is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. The company reported ($0.69) EPS for the quarter, missing analysts' consensus estimates of ($0.57) by $0.12. JIANGSU YANGHE BREWERY JOINT-STOCK CO., LTD. Director & Head-Manufacturing Development. BEAM stock was sold by a variety of institutional investors in the last quarter, including Endurance Wealth Management Inc.. Shares of BEAM can be purchased through any online brokerage account. Looking back at BEAM historical stock prices for the last five trading days, on December 24, 2020, BEAM opened at $91.00, traded as high as $91.57 and as low as $85.82, and closed at $87.84. Beam Suntory Stock Symbol September 26, 2019 - by Arfan - Leave a Comment Alcoholic beverages market in us 2020 beam suntory launches exclusive whisky suntory beverage food limited stbff beam suntory india case study beam suntory The acquisition was completed on April 30, 2014, for a final cost of about $16 billion – when it was also announced that Beam would become a subsidiary of Suntory named Beam Suntory. Beam surviving the Merger as a wholly-owned subsidiary of Suntory Holdings. One share of BEAM stock can currently be purchased for approximately $118.57. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Beam Therapeutics does not currently pay a dividend. S&P 500 3,370.62 (+1.82%) DOW 27,483.57 (+2.07%) QQQ 274.87 (+1.81%) AAPL 110.24 (+1.35%) MSFT 206.29 (+1.96%) FB 267.21 (+2.24%) GOOGL 1,654.16 (+1.84%) AMZN … Its headquarters are in Chicago, Illinois. By. Company profile page for Beam Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information By. View which stocks have been most impacted by COVID-19. Beam Therapeutics' stock was trading at $21.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). By. Learn about financial terms, types of investments, trading strategies and more. Beam Therapeutics trades on the NASDAQ under the ticker symbol "BEAM.". Here’s what the news means for both spirits stocks. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings. In fact, since 2017, 21 medical cannabis stocks have soared by more than 1,000%. Fundamental company data provided by Morningstar and Zacks Investment Research. Owler reports jim beam pany behind announces beam stock market business news booze dynasties control 70 billion of world s liquor wealth suntory holdings crunchbase beam suntory. Twitter for Websites. Beam Therapeutics Inc. (BEAM) NasdaqGS - NasdaqGS Real Time Price. (Add your “outperform” vote. It has a research and clinical collaboration agreement with Magenta Therapeutics, Inc. Beam Therapeutics Inc. was founded in 2017 and is based in Cambridge, Massachusetts. MicroAd. ET by Tomi Kilgore Beam Therapeutics to offer 6.25 million shares in … Beam Therapeutics has received 60.87% “underperform” votes from our community. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Receive a free world-class investing education from MarketBeat. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. View analysts' price targets for Beam Therapeutics or view Wall Street analyst' top-rated stocks. Corporate Bonds and Ratings. Want to see which stocks are moving? 2, 2020 at 7:58 a.m. Get daily stock ideas top-performing Wall Street analysts. Trading volume was a total of 308.50K shares. Ticker table to check the latest price updates. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Trading volume was a total of 398.30K shares. Beam Therapeutics has received a consensus rating of Buy. The company earns $-78,330,000.00 in net income (profit) each year or ($14.05) on an earnings per share basis. Yet, with medical cannabis sales expected to triple by 2026, the market still offers significant profit potential. Beam Global: BEEM: Not Tradable: Envision Solar International, Inc. EVSI: Not Tradable: Beam Global *W EXP 12/30/2023: BEEMW: Envision Solar International Inc *W EXP 12/30/2023: EVSIW: Beam Global: BEEM: Envision Solar International Inc: EVSI: BEAM GLOBAL: NASDAQ: BEEMW: stock Listing Status: Beam Global: NASDAQ: BEEM: stock Listing Status: Beam Global: NASDAQ: BEEM: symbol View all of BEAM's competitors. View which stocks are hot on social media with MarketBeat's trending stocks report. New. whiskey . Looking for new stock ideas? Delta Air Lines or Southwest Airlines: Which Is a Better Buy As Vaccines Roll Out? View analyst ratings for Beam Therapeutics or view MarketBeat's top 5 stock picks. Since then, BEAM shares have increased by 458.0% and is now trading at $118.57. Top institutional investors include Endurance Wealth Management Inc. (0.00%). A high-level overview of Beam, Inc. (BEAM-OLD) stock. Beam Suntory Careers Jobs Zippia . Stock analysis for Beam Therapeutics Inc (BEAM:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. This suggests that the stock has a possible downside of 71.7%. Since then, BEAM stock has increased by 342.7% and is now trading at $94.08. 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Beam Therapeutics in the last twelve months. FreakOut Holdings. There are currently 1 hold rating and 5 buy ratings for the stock. Beam Suntory, Inc. is a subsidiary of Suntory Beverage & Food Ltd, which itself is a subsidiary of Suntory Holdings of Osaka, Japan. Do Not Sell My Information. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. The consensus among Wall Street research analysts is that investors should "buy" Beam Therapeutics stock. (BEAM) raised $101 million in an IPO on Thursday, February 6th 2020. Suntory Beverage & Food. Its business has expanded to other fields, and the company now also makes soft drinks and operates sandwich chains. (Add your “underperform” vote.). Learn more. Compare. Export data to Excel for your own analysis. And bought this instead! Symbol Type; Beam Therapeutics / Beam Therapeutics Inc. Common Stock: US XNAS: BEAM: EQ0000000064993591 Tradable: RHS: Fractional Shares: Listed: 2020-02-06 Beam Therapeutics Inc. BEAM: Tradable: Beam Therapeutics Inc: BEAM: BEAM THERAPEUTICS INC. NASDAQ: BEAM: stock Listing Status: Beam Therapeutics Inc. BEAM: S BEAM THERAPEUTICS INC COM: NSDQ: BEAM: EQ By. We are Beam Suntory As a world leader in premium spirits, Beam Suntory is inspiring human connections. Beam Suntory Inc Stock Symbol. Investor Relations (Management Policy, Earnings Releases, Financial Data,IR Library,Stock Information) for Suntory Beverage & Food Limited (SBF) Chart. You may vote once every thirty days. With a performance objective of being the world’s most admired and fastest growing premium spirits company, and a vision of Growing for Good, we're driving growth through quality craftsmanship, consumer connections and entrepreneurial spirit. J.P. Morgan, Jefferies and Barclays acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Its licensed technology platform, which includes access to base editing technologies and associated technologies that enhance the scope of base editing. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. Select market. What's going on at Beam Therapeutics (NYSE:BEAM)? Beam Therapeutics' management team includes the following people: Warren Buffett has been on a selling spree, Through Berkshire Hathaway…Warren Buffett recently dumped $800 million of Apple stock… Learn everything you need to know about successful options trading with this three-part video course. SUNTORY BEVERAGE FOOD AKTIE und aktueller Aktienkurs. ), Beam Therapeutics has received 14 “underperform” votes. Some companies that are related to Beam Therapeutics include BioNTech (BNTX), Novozymes A/S (NVZMY), CRISPR Therapeutics (CRSP), argenx (ARGX), Bio-Techne (TECH), QIAGEN (QGEN), Repligen (RGEN), Fate Therapeutics (FATE), Neurocrine Biosciences (NBIX), Twist Bioscience (TWST), Adaptive Biotechnologies (ADPT), Denali Therapeutics (DNLI), Novavax (NVAX), Acceleron Pharma (XLRN) and Iovance Biotherapeutics (IOVA). Pareteum Announces … Jim Beam, Jack Daniels, and Jose Cuervo-Jim Beam is a brand of bourbon whiskey produced in Clermont, Kentucky by Beam Suntory. SHANXI XINGHUACUN FEN WINE FACTORY CO.,LTD. Beam Therapeutics has a market capitalization of $6.87 billion and generates $20,000.00 in revenue each year. Baidu. XL Fleet (NYSE:XL) Stock: The Next Big EV Company? The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.01 million. Twitter. Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. Wall Street analysts have given Beam Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Suntory News & Media. View breaking news headlines for BEAM stock from trusted media outlets at MarketBeat. 49.79% of the stock of Beam Therapeutics is held by institutions. Beam Global Asia Linkedin. Based on aggregate information from My MarketBeat watchlists, some companies that other Beam Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Editas Medicine (EDIT), Cisco Systems (CSCO), Square (SQ), Skyworks Solutions (SWKS), Akoustis Technologies (AKTS), Invitae (NVTA), QUALCOMM (QCOM) and Alector (ALEC). Beam Therapeutics has only been the subject of 1 research reports in the past 90 days. All rights reserved. Analysten schätzen den Umsatz des Unternehmens auf etwa 4 Milliarden US-Dollar im Jahr. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. To see all exchange delays and terms of use please see disclaimer. Learn more. Beam Therapeutics' mailing address is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. Sign-up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Beam Therapeutics' stock is owned by many different retail and institutional investors. View Beam Therapeutics' earnings history. More about American Brands Medical cannabis stocks have delivered solid gains over the last 3 years. Home Dividend Stocks Consumer Staples Consumer Products Beverages Beam … In January 2014, Suntory announced a deal to buy Beam Inc. for about $13.6 billion. Date & Time: Monday, 04 January 2021, 15:00 (JST) Share. With its 2014 acquisition of Beam, Inc., it has … See what's happening in the market right now with MarketBeat's real-time news feed. The company was founded by David R. Liu, Feng Zhang and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA. Their forecasts range from $31.00 to $40.00. Please log in to your account or sign up in order to add this asset to your watchlist. Select share. Beam Therapeutics (BEAM) has the following price history information.